FDA accepts Larotrectinib New Drug Application and Grants Priority Review
The FDA has accepted the NDA and granted Priority Review…
The FDA has accepted the NDA and granted Priority Review for larotrectinib for advanced or metastatic solid tumours harbouring a NTRK gene fusion...